TLDR
- Moderna stock jumped 10% as FDA panel backed its seasonal flu vaccine.
- MRNA gained momentum from flu approval hopes and pipeline expansion plans.
- Moderna’s Science Day update highlighted oncology and CAR-T programs.
- Analysts remain split as Moderna balances pipeline growth with losses.
- Cash reserves support Moderna as it pushes beyond COVID vaccine revenue.
Moderna gained fresh market momentum after a unanimous flu vaccine vote strengthened its post-COVID recovery story. MRNA stock rose 10.01% to $79.76, then reached $80.84 after hours. The move reflected renewed confidence in its vaccine pipeline and broader mRNA strategy.
FDA Panel Vote Gives Moderna a New Catalyst
The rally followed a 9–0 FDA advisory panel vote on Moderna’s mRNA-1010 seasonal flu vaccine. The panel backed its benefit-risk profile for adults aged 50 to 64 and seniors aged 65 and above. The vote improved expectations before the August 5, 2026, PDUFA decision date.
Regulators supported full approval for adults aged 50 to 64 and accelerated approval for older adults. Moderna gained a clearer path toward a second major commercial product after COVID vaccines. The flu program now gives the company a near-term catalyst with direct revenue potential.
The vote also changed the tone around MRNA stock after months of pressure from weaker COVID demand. Traders had already reacted to earlier mFLUSIVA updates, and the latest decision added force. The stock’s sharp move showed stronger interest in Moderna’s next growth phase.
Pipeline Expansion Supports the Breakout
Moderna also used its Science Day update to broaden its story beyond infectious disease vaccines. The company highlighted work in oncology, autoimmune disease, rare disorders, and advanced mRNA therapies. These updates helped position Moderna as a wider mRNA medicines company.
The company outlined programs including mRNA-2808 for multiple myeloma and mRNA-2151 for ovarian cancer. It also plans to begin clinical development of mRNA-6007, an in vivo CAR-T program, in 2027. These programs added momentum to the company’s longer-term pipeline narrative.
Moderna also emphasized AI, machine learning, automation, and robotics across research and development. The company aims to speed discovery and improve execution while reducing development friction. The pipeline still needs clinical progress before it can reshape revenue.
Analysts Weigh Growth Potential Against Timeline
Analysts remain split on Moderna’s near-term upside and long-term commercial pace. Piper Sandler raised its price target to $77 from $69 and kept an Overweight rating. Jefferies maintained a Hold rating with a $45 target and pointed to slower flu revenue timing.
The company still faces financial pressure as it funds multiple research programs. Moderna reported about $389 million in quarterly revenue and $1.94 billion in trailing 12-month revenue.It also posted a quarterly net loss of roughly $1.34 billion.
Even so, Moderna holds about $5.21 billion in cash and short-term investments. Its current ratio of 2.4 gives it flexibility as development spending continues. With flu approval pending and pipeline interest rising, MRNA stock has returned to a key breakout phase.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
